Biotechnology

Friday Nov 07, 2025 - 3:14 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy

Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug…

Thursday Nov 06, 2025 - 3:44 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results

Soligenix (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302’s potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. Leveraging its experience with hypericin-based therapies, Soligenix aims to address…

Friday Oct 24, 2025 - 3:26 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market

NRx Pharmaceuticals (NASDAQ: NRXP) was featured in a recent article that discussed its approach to bring preservative-free ketamine-based therapies to market, pursuing distinct regulatory and commercial pathways for both KETAFREE(TM) and NRX-100. “The company recently refiled an Abbreviated New Drug Application (‘ANDA’) for KETAFREE(TM), a preservative-free intravenous (‘IV’) ketamine formulation intended for all currently approved ketamine indications,” the article reads. “This filing follows the U.S.…

Friday Oct 17, 2025 - 2:46 pm

InvestorNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second…

Friday Oct 17, 2025 - 2:12 pm

InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and…

Thursday Oct 16, 2025 - 2:16 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the company to re-file its Abbreviated New Drug Application (‘ANDA’) for the product, which it has now done, a key step in bringing it to market,” reads a recent article. “Currently,…

Thursday Oct 16, 2025 - 1:22 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems… The VALID-ECG study results carry significant…

Tuesday Oct 14, 2025 - 3:34 pm

InvestorNewsBreaks – RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment

Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026. This comes “in the wake of its optimistic…

Wednesday Oct 08, 2025 - 3:19 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) on the Beat of Cardiac Innovation

HeartBeam (NASDAQ: BEAT) is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. A recent article discussing this reads, “HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease of use. This innovation is poised to reduce the burden…

Wednesday Oct 08, 2025 - 2:24 pm

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved ketamine indications. This follows FDA approval of NRx’s Suitability Petition… KETAFREE(TM) is designed to eliminate benzethonium chloride (“BZT”), a known neurotoxic and cytotoxic preservative still present in many ketamine formulations. NRx previously submitted a Citizen Petition…

Friday Sep 26, 2025 - 2:04 pm

InvestorNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) ECG System Offers Real-Time Cardiac Insights

HeartBeam (NASDAQ: BEAT) is positioned amid limitations of traditional 12-lead electrocardiogram (“ECG”) systems, often including cumbersome setups and restricted accessibility. The company “is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims…

Wednesday Sep 24, 2025 - 3:41 pm

InvestorNewsBreaks – Solving the Value-Based Care Puzzle: Adageis Brings Clarity with AI

Adageis, a growing healthcare technology company with a patented AI-driven platform, is positioning its software as a practical solution for providers seeking clarity in the transition from fee-for-service to value-based care. “By focusing on simplicity, contract visibility, and measurable financial outcomes, the firm aims to address one of the most pressing challenges in U.S. healthcare: how to reward high-quality care with appropriate compensation,” reads a…

Friday Sep 19, 2025 - 1:11 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology. “Nutriband’s FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product’s potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls (‘CMC’) plans spanning the…

Tuesday Sep 09, 2025 - 3:48 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Scales Manufacturing, Eyes Global Commercialization of AVERSA(TM)

Nutriband (NASDAQ: NTRB) was featured in a recent publication that discussed the company’s milestones, innovative platform, and lead product, AVERSA(TM) Fentanyl. NTRB’s technology “incorporates aversive agents into fentanyl patches to prevent misuse and accidental exposure. The company has built a global IP protection strategy, securing patents across the United States, Europe, Asia and Australia. With commercialization manufacturing scaled up in collaboration with Kindeva, Nutriband is…

Tuesday Sep 09, 2025 - 2:26 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently released second quarter 2025 financial results and provided an update on clinical programs. “The company emphasized progress toward an NDA submission for its lead asset CNM-Au8® in ALS, expected in the fourth quarter of 2025,”…

Friday Aug 29, 2025 - 2:56 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for amyotrophic lateral sclerosis (“ALS”), toward a potential FDA accelerated approval. “Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months could be major valuation catalysts for investors… Clene is preparing to…

Tuesday Aug 26, 2025 - 3:39 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Paves Way to Redefine Cardiac Care

HeartBeam (NASDAQ: BEAT) has secured foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system. “The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system enables patients and physicians to access critical arrhythmia data outside traditional clinical settings,” reads a recent article. “With the clearance secured, HeartBeam plans to expand access…

Friday Jul 25, 2025 - 3:25 pm

InvestorNewsBreaks – Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions

According to a recent article, “Behçet’s disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Europe… Behçet’s disease is believed to be an autoimmune illness with both genetic and environmental components. Symptoms are most severe in young adulthood and generally ameliorate with age… Treatment involves medications designed to ease symptoms and prevent serious complications, such as…

Wednesday Jul 16, 2025 - 11:23 am

InvestorNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its national network of mental health clinics through its subsidiary, HOPE Therapeutics, and advancing its proprietary NMDA-based therapies toward FDA approval. HOPE recently announced plans to deploy $10.3 million in total acquisition capital to purchase clinics that provide interventional psychiatric care focused on neuroplastic therapies like transcranial magnetic…

Friday Jul 11, 2025 - 2:29 pm

InvestorNewsBreaks – Rare Biotech Story: Nutriband Inc. (NASDAQ: NTRB) Founder Shares Vision in Smart Money Circle Podcast

Nutriband (NASDAQ: NTRB) was recently featured on the Smart Money Circle Show, where Serguei Melnik, NTRB’s founder and president, unveiled his no-nonsense approach to biotech entrepreneurship. Standing in stark contrast to the conventional playbook are his grounded tone and unwavering focus on long-term value. An article discussing this reads, “Unlike most early-stage biotech companies, Nutriband generates revenue today. The company operates a manufacturing facility in…

Wednesday Jul 09, 2025 - 1:20 pm

InvestorNewsBreaks – Adageis’ Platform Tackles Healthcare Complexities with AI

Adageis was featured in a recent article that discussed its powerful and patented AI-centric software solution. “Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Adageis’ CEO Shane Speirs was quoted as saying. “What Adageis does is provide a simple solution to healthcare organizations, ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a…

Tuesday Jul 08, 2025 - 2:48 pm

InvestorNewsBreaks – Why HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. “HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection, but also…

Monday Jun 30, 2025 - 3:31 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance

Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and…

Monday Jun 30, 2025 - 1:05 pm

InvestorNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent…

Thursday Jun 26, 2025 - 3:50 pm

InvestorNewsBreaks – Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities…

Thursday Jun 12, 2025 - 12:54 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases. The company recently announced its financial results for the first quarter of 2025 as well as accomplishments representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. “Our strategic focus remains on advancing our clinical programs, and we…

Tuesday Jun 10, 2025 - 12:52 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of…

Friday Jun 06, 2025 - 1:33 pm

InvestorNewsBreaks – Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

Intelligent Bio Solutions (NASDAQ: INBS) is a medical technology company pioneering rapid, non-invasive diagnostics through its proprietary Intelligent Fingerprinting Drug Screening System. INBS was featured in a recent article that reads, “By utilizing fingerprint sweat analysis, the company offers a cost-effective, hygienic solution to detect recent drug use — targeting substances commonly found in workplace settings… The company’s vision is to redefine drug screening by…

Wednesday Jun 04, 2025 - 3:34 pm

InvestorNewsBreaks – Adageis Empowers Providers with Actionable Insights for Value-Based Care Success

Adageis, a growing healthcare technology company, offers a unique streamlined and AI-powered software solution designed to make the shift toward value-based care simpler for healthcare practices. “At the core of the company’s offering is the ProActive Care Platform, a patented, AI-centric engine that enables providers, health systems, ACOs, and CINs to identify and act on high-value opportunities within their existing operations,” reads a recent article.…

Friday May 30, 2025 - 3:07 pm

InvestorNewsBreaks – Adageis’ AI-Powered Insights Aim to Improve Outcomes, Revenue Forecasting

Adageis, a forward-thinking healthcare technology company, has a comprehensive suite of AI-powered solutions aimed at providers shifting from fee-for-service to value-based care. “At the core of the company’s offering is its ProActive Care Platform, which combines predictive analytics with real-time data integration to improve both clinical and financial outcomes,” reads a recent article. “The platform’s Patented Risk Engine (‘PRE’) enables users to forecast revenue based…

Thursday May 22, 2025 - 3:31 pm

InvestorNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of…

Thursday May 22, 2025 - 2:50 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy…

Thursday May 15, 2025 - 3:36 pm

InvestorNewsBreaks – Adageis’ Fintech Platform Drives Smarter, More Profitable Healthcare

Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based…

Thursday May 15, 2025 - 2:32 pm

InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances

Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch…

Thursday May 15, 2025 - 12:54 pm

InvestorNewsBreaks – Zacks Research Issues Business Update as Soligenix Inc. (NASDAQ: SNGX) Continues Enrollment in Confirmatory Phase 3 HyBryte Trial

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success. According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with…

Friday May 09, 2025 - 2:51 pm

InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its innovative RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. In addition, Calidi’s virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation. “Targeting tumors with a systemic virotherapy with a…

Thursday May 08, 2025 - 3:32 pm

InvestorNewsBreaks – Adageis’ AI-Powered Platform Empowers Smarter Billing, Better Care

Adageis, a healthcare technology company, is transforming how providers manage insurance payments with its AI-driven software platform, designed to enhance transparency, ensure reimbursement, and support the shift to value-based care. By offering real-time insights into expected payments, identifying reimbursement gaps, and evaluating performance, Adageis empowers clinics—especially smaller or new practices—to optimize revenue, negotiate better insurance contracts, and make informed financial decisions. The platform helps providers…

Tuesday Apr 29, 2025 - 12:20 pm

InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a noninvasive, well-tolerated alternative that targets malignant T-cells with precision. With…

Tuesday Apr 29, 2025 - 11:14 am

InvestorNewsBreaks – Adageis Is Reshaping Patient Care Through Smart Tech

Adageis is revolutionizing healthcare with its flexible, AI-centric software solutions and ProActive Care Platform, built to eliminate administrative burdens and enable providers to focus on patients. With simplicity core to its design, the platform empowers healthcare organizations by identifying missed revenue opportunities from insurers and guiding providers to secure rightful payments. Using predictive analytics through its Patented Risk Engine (“PRE”), Adageis enhances steady cash flow…

Friday Apr 11, 2025 - 3:37 pm

InvestorNewsBreaks – Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions